What Klion D Treats: Main Uses and Benefits

The medication is commonly used in the local management of vaginitis infection, particularly when symptoms arise from a mixed etiology. This is relevant for conditions associated with the co-existence of susceptible fungi, such as Candida albicans, bacteria, and protozoa, including Trichomonas vaginalis.

The combination therapy is considered relevant for addressing mixed vaginal infections, candidal vulvovaginitis, and bacterial vaginosis. It is typically applied to address the symptomatic burden of active infection, specifically targeting localized inflammatory discomfort and symptoms related to physical discomfort. This helps address symptom clusters that may become intense or disruptive, such as vaginal itching, burning, and abnormal vaginal discharge.

The treatment is intended to assist in managing episodes involving recurrent or episodic manifestations where short-term symptomatic assistance is needed.

“The combination is relevant for managing conditions characterized by complex microbial etiology.”

Quick Fact: Relief for Localized Discomfort
Symptom Focus: Vaginal itching, burning, irritation, and abnormal discharge.
Clinical Context: Used in situations involving recurrent, acute, or mixed microbial infections.
Patient Benefit: Contributes to improved comfort during symptomatic periods and helps reduce the overall symptom load.

Eligibility Profile: Who Can and Cannot Use Klion D?

This drug is contraindicated for specific patient populations as defined in official regulatory documents. Use is strictly prohibited for the following populations:

Population Status	Eligibility Classification	Official Constraint
Allergy/Hypersensitivity	Contraindicated	Known hypersensitivity to metronidazole, miconazole, or any other ingredient in the formulation.
Pregnancy	Contraindicated	Use during the first trimester of pregnancy.

---

For other groups, use is either not recommended or requires special medical consideration:

• Children and Virgins: The product is generally not recommended for use in children under 12 or for patients who have not yet had sexual intercourse.
• Physiological Impairment: Use requires caution and close monitoring in patients with severe hepatic impairment (liver function disorders), renal failure, diseases of the central nervous system, or a history of blood production disorders (hematopoiesis).
• Lactation: Use is prohibited for breastfeeding mothers; nursing must be interrupted during treatment and for 24–48 hours after the last dose.

Additionally, use of alcoholic beverages is forbidden during therapy and for at least one day after cessation, and the product must not be used concurrently with barrier contraceptives (diaphragms or condoms) as the formulation may damage the latex material.

The interaction profile of Klion D, which combines Metronidazole and Miconazole Nitrate, is based on the potential systemic effects of both active ingredients, even with local application. The following interactions and restrictions are documented in official regulatory sources.

Prohibited Concurrent Agents and Substances

Co-administration with certain substances is strictly prohibited due to severe reaction risk or functional failure. These are categorized as contraindicated combinations.

• Disulfiram: Prohibited during treatment and within two weeks of the last dose due to the risk of psychotic reactions.
• Alcohol (Ethanol): Consumption of alcohol or products containing Propylene Glycol is prohibited during treatment and for at least 24 hours to three days after the final dose due to the risk of a severe disulfiram-like reaction.
• Vaginal Barrier Contraceptives: Use of latex condoms or vaginal diaphragms is prohibited concurrently, as the suppository excipient base may interact with the rubber materials, causing damage and failure.

Documented Pharmacokinetic Interactions

The components may alter the systemic exposure of certain co-administered drugs.

• Coumarin Anticoagulants (e.g., Warfarin): Both Metronidazole and Miconazole may increase the anticoagulant effect, requiring monitoring of Prothrombin Time and INR.
• Cimetidine: May decrease the plasma clearance and prolong the half-life of Metronidazole, increasing systemic exposure.
• HMG-CoA Reductase Inhibitors (Statins): Miconazole may increase the plasma concentrations of certain statins, such as Lovastatin and Simvastatin, raising the risk of toxicity.
• Lithium: Co-administration with Metronidazole has been associated with the potential for elevated plasma lithium concentrations.

Mechanism 1: Disruption of Anaerobic DNA Integrity

This domain covers the action of Metronidazole, a prodrug that is selectively activated within the low-oxygen environments characteristic of susceptible anaerobic bacteria and protozoa. Once inside the microbe, electron-transfer proteins reduce the drug to highly reactive nitro radical anions, which then bind to and damage the pathogen's DNA. This molecular cascade results in the irreversible inhibition of nucleic acid synthesis, leading to loss of cell viability in the targeted organisms.

---

️ Mechanism 2: Fungal Cell Membrane Structural Blockade

This domain describes how Miconazole Nitrate, an azole antifungal, inhibits the fungal cytochrome P450 enzyme 14alpha-demethylase. By blocking this enzyme, the drug prevents the production of ergosterol, a crucial structural component of the fungal cell membrane. The resulting accumulation of precursor sterols alters membrane structure and increases permeability. This action leads to the leakage of cellular contents and functional collapse, resulting in the loss of cell viability.

---

Complementary Dual-Action Physiological Effect

The core mechanism of Klion D is the complementary action of its two components, each utilizing a distinct pathway—one targeting the genetic material and the other the cell membrane structure. By addressing pathogens from two different microbial kingdoms, this dual-pronged strategy results in simultaneous disruption of both anaerobic DNA synthesis and fungal membrane formation at the site of administration.

Instruction Map: How to use Klion D — Administration Guidelines

---

Administration Scope

Instruction	Details
Route of administration:	Intravaginal (topical). The dose is not for oral use.
Dosing schedule:	One vaginal dose unit (tablet or suppository) per day. For certain infections, the regimen may involve concurrent systemic treatment of the sexual partner.
Timing in relation to meals (if applicable):	Not applicable, as the product is for topical use.
Preparation requirements (if applicable):	The vaginal tablet form is slightly moistened with water prior to insertion.
Age-group administration rules:	Generally not recommended for use in children under 12 years. The standard adult dose is typically used for elderly patients.
Missed-dose rules:	The standard approach is to resume administration with the next scheduled dose.
Special procedural conditions:	Treatment is not recommended during menstruation. The use of latex contraceptives (diaphragms or condoms) during treatment is typically avoided.

---

Instruction Classifications (High-Level)

Classification	Details
Administration method type:	Topical (Intravaginal).
Frequency pattern:	Once daily (q.d.).
Use-context constraints:	Includes a time-of-day constraint (in the evening, before bed) and may involve simultaneous partner treatment.

---

Resulting Procedural Structure

Step sequence:

• Prepare the dose unit (moistening the tablet, if applicable).
• Insert the dose unit while in a lying position.
• The dose is inserted high into the vagina.
• The administration is performed once daily in the evening.
• The course continues for the designated duration, typically 7 to 10 consecutive days.

---

Connection to the overall use protocol

These instructions establish the Intravaginal route and the once-daily frequency for the medicine's use. The protocol defines specific parameters, such as the preference for evening insertion and the avoidance of use during menstruation, while also noting when simultaneous partner treatment is part of the complete regimen.

Research Evidence / Overview of Studies for Klion D

---

Evidence for Use in Bacterial Vaginosis (BV)

The available research for this combination product is primarily made up of short-term Randomized Controlled Trials (RCTs) and Phase 3 studies. These studies evaluated symptomatic adult women with a confirmed diagnosis of bacterial vaginosis. The research primarily monitored the documentation of physical signs and pathogen clearance documentation over short intervals immediately following the course of therapy.

Studies reported patterns of pathogen clearance and changes in symptom measurements that were generally consistent across trials. However, long-term effects are not fully established, and existing research is limited in follow-up duration for recurrence patterns beyond a few months. Data for certain groups, such as women experiencing very frequent episodes, remain insufficient.

---

Evidence for Use in Mixed Vaginal Infections

The fixed-dose combination was studied for treating conditions characterized by fluctuating or episodic manifestations where multiple susceptible pathogens are present simultaneously. The primary research involved Phase 3 clinical trials that designed composite measurements to reflect the documentation of multiple pathogens and the simultaneous monitoring of symptoms.

Studies reported a consistent pattern in the observed short-term composite measurements related to the documentation of multiple pathogens. This evidence helps contextualize how patients reported their experience during episodes of heightened symptom activity. However, comparative evidence is lacking between this specific fixed-dose combination and the clinical strategy of using the two active agents administered separately.

---

Long-Term Studies and Follow-Up Data

Research has explored the product's role in the context of preventing recurrent infections using high-quality Randomized Controlled Trials (RCTs) with follow-up periods of up to 12 months. These studies primarily monitored the proportion of women who had a confirmed recurrence of either bacterial vaginosis or vulvovaginal candidiasis.

The long-term RCTs research describes patterns in the recurrence of Bacterial Vaginosis that were observed during the study. Conversely, recurrence measurements for vulvovaginal candidiasis were associated with patterns similar to those observed in the study. The research landscape has specific limitations, as long-term effects following standard short-course treatment are not well characterized.

Key Studies & References

1. Study Details | NCT01230814 | Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
2. Treatment and prevention of trichomoniasis, bacterial vaginosis and candidiasis with a new 7-day regime containing metronidazole and miconazole in a single vaginal pessary (Open, non-comparative study)

Common questions about Klion D (FAQ)

Q: How quickly should I expect to see results after starting Klion D?

Regulatory information indicates that the metronidazole component is rapidly absorbed. While the drug is absorbed, official product documents do not specify a patient-perceived timeline for when symptoms should begin to improve.

Q: What are the most common mild side effects people report when taking Klion D?

The official product information lists the most common mild adverse effects. These are typically local reactions at the application site, such as vaginal irritation, burning, itching (pruritus), and vaginal discharge. Systemic effects like headache and nausea are also commonly reported.

Q: Is it normal to experience a slightly altered taste while using Klion D?

Yes, this is common. The metronidazole component can be absorbed into the bloodstream, and official drug labels note that users frequently report experiencing a sharp, unpleasant metallic taste in the mouth.

Q: What happens if I miss a dose of Klion D – is it serious?

If a dose is missed, regulatory instructions generally advise applying the missed dose as soon as it is remembered. Instructions generally advise to skip the missed dose and resume the regular dosing schedule, if it is near the time of the next dose.

Q: Can Klion D be used during menstruation, or should treatment be paused?

According to the official product information, treatment with this medicine is generally not recommended during menstruation.

Q: What should I do if the Klion D tablet or pessary doesn't fully dissolve?

The official instructions for the vaginal tablet form advise moistening the tablet with a little water before insertion to aid dissolution. Regulatory documents do not provide specific patient troubleshooting advice for incomplete dissolution.

Q: What are the main benefits of using Klion D pessaries over oral tablets?

As a topical, intravaginal product, the primary benefit is targeted action at the site of infection. Regulatory sources show that the active ingredients are absorbed into the bloodstream at very low levels compared to oral forms, which helps limit systemic exposure and potential side effects throughout the body.

Q: Does Klion D require the partner to be treated as well, depending on the condition?

For certain infections, the official treatment regimen may require concurrent systemic treatment of the sexual partner. This is intended to prevent reinfection and ensure the complete resolution of the condition.

Q: How does Klion D work?

Klion D utilizes a dual-action mechanism due to its two active ingredients. Metronidazole works by damaging the DNA of susceptible protozoa and anaerobic bacteria, while Miconazole Nitrate works by disrupting the cell membrane structure of fungi.

Q: How often is Klion D typically taken or applied during the treatment period?

Official documentation indicates that the medicine is administered once daily, usually in the evening. The specific duration of the treatment course is determined by the prescribing professional.

Q: Does Klion D cause tiredness or drowsiness that could affect driving?

Dizziness or drowsiness has been listed as a possible side effect, particularly linked to the metronidazole component. Official warnings note that care should be taken when performing tasks that require alertness, such as driving or operating machinery.

Q: Is there any research evidence supporting the use of Klion D for bacterial infections?

Studies and regulatory documents confirm that the product has been evaluated in clinical trials for its efficacy in treating bacterial vaginosis (BV) and mixed vaginal infections, both of which involve susceptible bacterial components.

Q: Can men use Klion D, and if so, for what conditions?

The product is specifically formulated and labeled for intravaginal use in women. Although the male sexual partner may sometimes require concurrent systemic (oral) treatment for certain infections, the vaginal suppository form itself is not intended for use by men.

Q: What is the difference between Klion D and similar treatments like Flagyl (metronidazole)?

Klion D is a fixed-dose combination product containing two active ingredients: metronidazole and the antifungal miconazole nitrate. In contrast, Flagyl is a brand name for a product containing only the single ingredient metronidazole.

Q: How long does the Klion D treatment course typically last?

The required duration of the treatment course is determined by the prescribing professional. Regulatory instructions generally state that the course of treatment typically lasts for 7 to 10 consecutive days.

Q: Is Klion D safe for people with known liver or kidney problems?

Caution is required for patients with liver failure or severe hepatic impairment. Use with caution is also advised in patients with renal impairment (kidney problems) due to the risk of accumulation of the drug’s metabolites.

Q: How to use Klion D?

The official instructions indicate the product is for intravaginal use and is inserted while the patient is lying down, typically once daily in the evening. The medicine must not be swallowed.

Q: What are the functions of Miconazole Nitrate and Metronidazole in the Klion D formulation?

The formulation is designed to provide comprehensive microbial coverage. Metronidazole serves as the antibacterial and antiprotozoal component, while Miconazole Nitrate serves as the azole antifungal component.

Q: Are there any long-term side effects associated with repeated use of Klion D?

Official research focuses on short-course treatment, and long-term effects are not fully characterized. Prolonged or repeated use has been associated with a potential, rare risk of serious neurological effects, such as peripheral neuropathy, linked to the metronidazole component.

Q: Why do some people report stomach upset or nausea when taking Klion D?

Nausea is listed as a common systemic side effect in official documents. This is considered a common systemic side effect that occurs due to the small amount of the metronidazole component absorbed into the bloodstream.

Q: Is Klion D safe to use for women who are not sexually active?

According to official product information, use is generally not recommended for patients who are not sexually mature or who have not yet had sexual intercourse.

Q: Are allergic reactions to Klion D common, and what are the symptoms?

A known hypersensitivity or allergy to any component of the medicine is a contraindication (a reason not to use it). While serious allergic reactions, such as anaphylactic reaction or angioedema, are listed as rare, symptoms of any allergy could include itching, swelling, or difficulty breathing.

Q: Does Klion D need to be stored in the refrigerator or at room temperature?

Official storage instructions require the medicine to be kept at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F). The product must be protected from light and moisture and should not be frozen.

Q: Are there any specific populations where Klion D is not recommended, like the elderly?

The standard adult dose is used for elderly patients. However, the product is specifically not recommended for children under 12 years of age or for women during the first trimester of pregnancy.

Q: How soon after stopping Klion D can I resume consuming alcohol safely?

Official warnings state that alcohol consumption should be avoided during treatment and for a period of at least 24 hours to three days following the final dose, due to the risk of a severe disulfiram-like reaction.

Q: Is it possible to develop resistance to Klion D over time?

While regulatory documents do not specify the likelihood of resistance with this combination product, clinical sources acknowledge that resistance to the metronidazole component can be a concern with certain organisms.

Q: What happens if Klion D is accidentally swallowed?

The medicine is strictly for intravaginal use and must not be swallowed. In the event of accidental oral ingestion, large amounts may lead to symptoms such as nausea, vomiting, or difficulties with muscle coordination (ataxia).

Q: Is it possible to use Klion D for too long?

The medicine is intended for short-course treatment. Regulatory warnings indicate that prolonged or repeated use may increase the risk of rare, serious adverse effects associated with the metronidazole component.

Q: Can taking Klion D cause a temporary metallic taste in the mouth?

Yes, regulatory documents list this as a common, temporary side effect. The metallic taste is associated with the systemic absorption of the metronidazole component.

How to Store and Dispose of Klion D 100 Vaginal Tablets

Official regulatory guidelines mandate specific storage and disposal requirements for Klion D to maintain the stability of the Metronidazole and Miconazole Nitrate combination and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F), and store below 30 C.
Environment	Protect from light and moisture, and do not freeze the product.
Container	Keep the medicine in the original container; do not use if the packaging is damaged.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Klion D must be handled as pharmaceutical waste. Do not dispose of the tablets by flushing them down the toilet or placing them in household trash. Dispose of the unused product according to local regulations or return it to an authorized collection point.